Business
Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting
MARSEILLE, France, April 29, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today shared new preclinical data for IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2025.
About this update from Innate Pharma Sa Class A
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/2e1410b1c4f83ee96f63b5a6b6c63818"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kP0pEM0t7_gWOSTI8jhlzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2e1410b1c4f83ee96f63b5a6b6c63818","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/CsdHbRW150Ghm5JmWuUj6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/2e1410b1c4f83ee96f63b5a6b6c63818","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"IPH4502 is a differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors.","length":137,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"IPH4502 demonstrated superior preclinical anti-tumor activity compared to enfortumab vedotin (EV) in urothelial carcinoma models with low or heterogeneous Nectin-4 expression, as well as in models resistant to EV.","length":213,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"IPH4502 showed strong preclinical activity across multiple tumor types, including triple-negative breast cancer, head and neck, and esophageal cancers, supporting its potential for broad clinical application.","length":208,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":558,"olType":false},{"type":"text","content":"MARSEILLE, France, April 29, 2025--(BUSINESS WIRE)--Regulatory News:","length":68,"tagName":"p"},{"type":"text","content":"Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today shared new preclinical data for IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2025.","length":352,"tagName":"p"},{"type":"text","content":"Nectin-4 targeting is validated by enfortumab vedotin (EV), an ADC with a monomethyl auristatin E (MMAE) payload, approved for urothelial carcinoma (UC), an indication with high Nectin-4 expression. However, EV ...